Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 6/20 | 0.33 |
| ▸ | MAOA | P21397 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11121 | 0.77 | ABCG2 (0.50) | SMN1; SMN2NPC1LMNARAB9AMAOB | |
| SCHEMBL1842960 | 0.74 | ITGB2 (0.60) | POLBSMN1; SMN2LMNACASP6MAOB | |
| SCHEMBL1840582 | 0.74 | ABCG2 (0.60) | SMN1; SMN2TP53NPC1LMNARAB9A | |
| SCHEMBL12481704 | 0.73 | AHR (0.42) | — | |
| SCHEMBL30536492 | 0.71 | STS (0.45) | POLBCASP6ABCG2ITGB2ICAM1 | |
| SCHEMBL3033164 | 0.71 | STS (0.45) | POLBCASP6ABCG2ITGB2ICAM1 | |
| SCHEMBL3138976 | 0.71 | POLB (0.41) | POLBTP53CASP6ALDH1A1CYP3A4 | |
| SCHEMBL5306227 | 0.71 | POLB (0.41) | POLBTP53CASP6ALDH1A1CYP3A4 | |
| SCHEMBL1559532 | 0.69 | SYK (0.38) | POLBSMN1; SMN2TP53NPC1LMNA | |
| SCHEMBL23657991 | 0.68 | LMNA (0.65) | SMN1; SMN2LMNAMAOBMAOAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768970-B1 | SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | claimed |
| US-8853263-B2 | Co-therapy for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | claimed |
| EP-1968572-B1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-06 | — | — | EP | claimed |
| EP-2276481-B1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF ANXIETY | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-30 | — | — | EP | claimed |
| US-8497298-B2 | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-30 | — | — | US | claimed |
| EP-1976507-B1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPTOGENESIS | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-05 | — | — | EP | claimed |
| WO-2012040133-A3 | NOVEL PRECURSORS OF RADIOLABELLED CHOLINE ANALOG COMPOUNDS | GE HEALTHCARE LIMITED (GB) | 2012-05-10 | — | — | WO | claimed |
| EP-1968574-B9 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-09 | — | — | EP | claimed |
| US-20120065257-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | SMITH-SWINTOSKY VIRGINIA L (US) | 2012-03-15 | — | — | US | claimed |
| US-8084490-B2 | Sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-27 | — | — | US | claimed |
| WO-2007075752-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-05 | — | — | WO | claimed |
| WO-2007075751-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-05 | — | — | WO | claimed |
| WO-2007075833-A2 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-05 | — | — | WO | claimed |
| WO-2007075834-A2 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-05 | — | — | WO | claimed |
| US-20070155824-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR DISEASE MODIFICATION / EPILEPTOGENESIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | claimed |
| EP-1768970-A1 | SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-04 | — | — | EP | claimed |
| US-20060041008-A1 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | US | claimed |
| WO-2006007435-A1 | SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-19 | — | — | WO | claimed |
| WO-2006007436-A1 | SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-19 | — | — | WO | claimed |
| US-20050282887-A1 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155824-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR DISEASE MODIFICATION / EPILEPTOGENESIS | STS, GABRB2, SULT2A1 | POLB 3558/4885SMN1; SMN2 624/4885TP53 4545/4885 |
| US-20060041008-A1 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | SULT2A1, STS, GRIK5 | POLB 4415/4885SMN1; SMN2 537/4885TP53 4807/4885 |
| US-20050282887-A1 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | SULT2A1, STS, GRIK5 | POLB 4415/4885SMN1; SMN2 537/4885TP53 4807/4885 |
| US-20120065257-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | CNR2, FAAH2, CCKBR | POLB 4390/4885SMN1; SMN2 1516/4885TP53 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.